Impact of TSH stimulation on ۲-[۱۸F]FDG PET/CT results in patients with papillary thyroid carcinoma presented with elevated serum thyroglobulin level and negative diagnostic iodine-۱۳۱ whole-body scan

Publish Year: 1401
نوع سند: مقاله ژورنالی
زبان: English
View: 274

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IRJNM-30-2_002

تاریخ نمایه سازی: 8 تیر 1401

Abstract:

Introduction: ۲-[۱۸F]fluoro-۲-deoxy-D-glucose-positron emission tomography/computed tomography (۲-[۱۸F]FDG-PET/CT) is implemented in papillary thyroid cancer (PTC) patients with elevated Thyroglobulin (Tg) and negative Iodine-۱۳۱ whole-body scan (۱۳۱I-WBS). Here, we evaluated the impact of TSH stimulation after levothyroxine withdrawal on the detection rate of ۲-[۱۸F]FDG-PET/CT.Methods: A prospective study was performed on ۶۰ PTC patients, presented with negative ۱۳۱I-WBS and elevated or unjustifiably high Tg. ۲-[۱۸F]FDG-PET/CT was performed in ۳۰ patients while they were on levothyroxine therapy (unstimulated-TSH [uns-TSH]) and after Levothyroxine withdrawal in the other ۳۰ patients (stimulated-TSH [s-TSH]). Results of the two groups were compared using nonparametric tests. Receiver operating characteristic curve was used to find Tg cutoff values for predicting positive scan results.Results: Overall, ۲-[۱۸F]FDG-PET/CT was positive in ۶۳.۳% of the patients, ۸۰% (۲۴/۳۰) in s-TSH and ۴۶.۷% (۱۴/۳۰) in uns-TSH group. The detection rate was higher in s-TSH group (p=۰.۰۰۷). It was still significant in multiple regression analysis (p=۰.۰۴۱). In uns-TSH group, ۲-[۱۸F]FDG-PET/CT was more often positive in patients with higher uns-Tg level (p=۰.۰۰۲). An uns-Tg level of ≥۱۹.۰۰ ng/mL predicted positive results with the sensitivity of ۰.۷۸۶ and specificity of ۰.۷۵۰ (area under curve=۰.۸۱۹). Although statistically insignificant (p=۰.۰۵۵), s-Tg was higher in patients with positive ۲-[۱۸F]FDG-PET/CT studies in the s-TSH group. No relation was demonstrated between TSH and anti-Tg-antibody levels and ۲-[۱۸F]FDG-PET/CT positivity.Conclusion: TSH-stimulation after levothyroxine withdrawal might enhance the detection rate of ۲-[۱۸F]FDG-PET/CT in PTC patients. Additionally, ۲-[۱۸F]FDG-PET/CT is more often positive in patients with higher Tg levels.

Authors

Alireza Emami-Ardekani

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Fariba Ghorbani-Nik

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Najme Karamzade-Ziarati

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Reyhaneh Manafi-Farid

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Armaghan Fard-Esfahani

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Babak Fallahi

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Davood Beiki

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

Yalda Salehi

Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran

Mohammad Eftekhari

Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Caetano R, Bastos CRG, de Oliveira IAG, da Silva RM, ...
  • Kist JW, de Keizer B, Stokkel MP, Hoekstra OS, Vogel ...
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, ...
  • Chao M. Management of differentiated thyroid cancer with rising thyroglobulin ...
  • Fallahi B, Fard-Esfahani A, Emami-Ardekani A, Sahari S, Beiki D, ...
  • Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I. ۱۸ F-FDG ...
  • Abraham T, Schöder H. Thyroid Cancer—Indications and Opportunities for Positron ...
  • Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, ...
  • Ahn B-C. Personalized medicine based on theranostic radioiodine molecular imaging ...
  • Lin EC, Alavi A. PET and PET/CT. A Clinical Guide. ...
  • Kukulska A, Krajewska J, Kołosza Z, Paliczka-Cieslik E, Puch Z, ...
  • Bläser D, Maschauer S, Kuwert T, Prante O. In vitro ...
  • Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, ...
  • Ma C, Xie J, Lou Y, Gao Y, Zuo S, ...
  • Deichen J, Schmidt C, Prante O, Maschauer S, Papadopoulos T, ...
  • Qichang W, Lin B, Gege Z, Youjia Z, Qingjie M, ...
  • Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani ...
  • National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer ...
  • Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, ...
  • Giovanella L, Trimboli P, Verburg FA, Treglia G, Piccardo A, ...
  • Saghari M, Gholamrezanezhad A, Mirpour S, Eftekhari M, Takavar A, ...
  • Crippa F, Alessi A, Gerali A, Bombardieri E. FDG-PET in ...
  • Almuhaideb A, Papathanasiou N, Bomanji J. ۱۸F-FDG PET/CT imaging in ...
  • Agrawal A, Rangarajan V. Appropriateness criteria of FDG PET/CT in ...
  • Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, ...
  • Marcus C, Whitworth PW, Surasi DS, Pai SI, Subramaniam RM. ...
  • Ma C, Kuang A, Xie J, Ma T. Possible explanations ...
  • Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role ...
  • Chai H, Zhang H, Yu Y-l, Gao Y-c. Optimal threshold ...
  • Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, ...
  • Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, ...
  • Choi SJ, Jung KP, Lee SS, Park YS, Lee SM, ...
  • Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. ...
  • نمایش کامل مراجع